This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ueki, K. Articles by Kirino, T. Search for Related Content PubMed PubMed Citation Articles by Ueki, K. Articles by Kirino, T.

Correlation of Histology and Molecular Genetic Analysis of 1p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A in 91 Astrocytic and Oligodendroglial Tumors¹

Department of Neurosurgery, University of Tokyo Hospital, Tokyo 113-8655 [K. U., A. M., A. A., T. K.]; Departments of Neurosurgery [R. N.] and Pathology [T. H.], Saitama Medical School Saitama 350-0495; First Department of Pathology, Gunma University Medical School [Y. N., J. H.] Maebashi 371-0034; Department of Pathology, Tokyo Metropolitan Komagome Hospital [N. F.] Tokyo 113-8677; Departments of Neurosurgery, Teikyo University Hospital [T. F., S. H.] Tokyo 173-8605; Tokyo Women’s Medical University [O. K.] Tokyo 162-8666; Tokyo Metropolitan Bokuto Hospital [T. I.] Tokyo 130-8575; Toranomon Hospital [M. U.] Tokyo 105-8470; Kanto Medical Center NTT-East [C. O.] Tokyo 141-0022; Tokyo Teishin Hospital [S. I.] Tokyo 102-8798; Tokyo Metropolitan Neurological Institute [H. T.] Tokyo 183-0042; and Core Research for Evolutional Science and Technology, Kawaguchi 332-0012 [T. K.], Japan

	ABSTRACT

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS Molecular Genetic Analysis. RESULTS DISCUSSION REFERENCES

 
Purpose: The histological diagnosis of human gliomas is of great importance for estimating patient prognosis and guiding therapy but suffers from being subjective and, therefore, variable. We hypothesized that molecular genetic analysis could provide a more objective means to classify tumors and, thus, reduce diagnostic variability.

Experimental Design: We performed molecular genetic analysis on 91 nonselected gliomas for 1p, 19q, 10q, TP53, epidermal growth factor receptor, and cyclin-dependent kinase 4 abnormalities and compared with the consensus diagnoses established among four independent neuropathologists.

Results: There were six astrocytomas, seven anaplastic astrocytomas, 45 glioblastomas, 21 oligodendrogliomas, eight anaplastic oligodendrogliomas, three oligoastrocytomas, and one anaplastic oligoastrocytoma. Twenty-nine cases had either 1p or 19qloss of heterozygosity (LOH) while retaining both copies of 10q, of which 25 (86%) were histologically oligodendroglioma, anaplastic oligodendroglioma, oligoastrocytoma, or anaplastic oligoastrocytoma. As for the oligodendroglial tumors, unanimous agreement of the initial diagnoses was almost restricted to those cases with combined 1p/19qLOH, whereas all nine tumors without 1p loss initially received variable diagnoses. Interestingly, TP53 mutation was inversely related to 1pLOH in all gliomas (P = 0.0003) but not 19qLOH (P = 0.15).

Conclusions: These data demonstrate that molecular genetic analysis of 1p/19q/10q/TP53 has significant diagnostic value, especially in detecting oligodendroglial tumors. In addition, 1pLOH and TP53 mutations in gliomas may be markers of oligodendroglial and astrocytic pathways, respectively, which may separate gliomas with the same histological diagnosis, especially oligodendroglial tumors and glioblastomas. Testing for those molecular genetic alterations would be essential to obtain more homogeneous sets of gliomas for the future clinical studies.

	INTRODUCTION

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS Molecular Genetic Analysis. RESULTS DISCUSSION REFERENCES

 
Treatment of diffuse gliomas still remains one of the toughest challenges in oncology. Surgical cure of these tumors infiltrating into the brain is practically impossible, and their clinical course is primarily determined by the biological behavior of the tumor cells, including growth rate and their responsiveness to radiation therapy and chemotherapy. For the prediction of such biological behavior, the most reliable, proven method has been the histological diagnosis based on the microscopic morphology of the tumor since the era of Bailey and Cushing. However, histological diagnosis suffers from being subjective and, therefore, variable in some cases, which occasionally hampers the clinical studies on gliomas. On the other hand, recent progress in the molecular biology and molecular genetics is showing a potential to provide new means to dissect the biological features of gliomas.

Various genetic alterations have been identified in the tumorigenesis and progression of diffuse gliomas (1, 2, 3, 4) . Amplification of oncogenes has been observed for EGFR,³ CDK4, and MDM2 genes (5 , 6) and inactivating mutation or deletion of tumor suppressor genes has been discovered for TP53(17p), RB(13q), CDKN2A(9p), PTEN(10q), and DMBT1(10q) (7, 8, 9, 10, 11) . Moreover, several chromosomal loci presumed to contain tumor suppressor genes, such as 1p, 19q, 11p, and 22q, show frequent allelic losses in gliomas, which are easily detected as LOH (2) . Among those, LOH at short arm of chromosome 1 (1p) and long arm of chromosome 19 (19q) is found in 60–70% of OGs (12, 13, 14, 15) , and recent studies demonstrated that 1pLOH in AOGs, frequently accompanied by 19qLOH, predicted sensitivity to specific chemotherapy and better overall survival (16 , 17) . Although the underlying molecular biological mechanism for this observation is yet unknown, 1pLOH seems to represent a specific biological feature of tumor cells, at least in OGs. On the other hand, 1pLOH is also found in 50–70% in OAs and 10–20% of astrocytic tumors, including GBMs (4 , 18) , and its significance within these histological types is not yet clear. Therefore, we studied a series of diffuse gliomas of various grades and histologies for a range of genetic markers known to be important in glioma tumorigenesis. Importantly, we carefully classified these 91 gliomas using independent histological review by four neuropathologists, enabling us to compare genotype with both individual and consensus diagnosis. In this manner, we sought to determine whether a cumulative analysis of those genetic markers could provide insight into the significance of molecular genetic examination in glioma diagnosis.

	MATERIALS AND METHODS

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS Molecular Genetic Analysis. RESULTS DISCUSSION REFERENCES

 
Tumor samples were obtained at surgery performed at the Saitama Medical School Hospital, Teikyo University Hospital, and University of Tokyo Hospital and its affiliated hospitals. In total, 91 cases of diffuse gliomas operated during the period of 1996–1999 were studied. Tumor samples were collected on an availability basis and were not selected for specific histological types. Portions of resected tumors were snap frozen in liquid nitrogen and stored at -80°C until use. DNA from the tumor tissue was extracted using QIAamp DNA Mini Kit (Qiagen, Valencia, CA) after the manufacturer’s protocol. Constitutional DNA used as a control for the microsatellite analysis was extracted as described previously from peripheral blood obtained after written informed consent (19) . All experiments using the human samples were approved by the ethical committee at the University of Tokyo Hospital.

Histology slides were reviewed by four independent neuropathologists (T. H., N. F., J. H., and Y. N.), and consensus diagnoses were made following the latest WHO classification (20) . In cases with divergent opinions, the senior neuropathologist (Y. N.) made the final diagnosis. For GBM cases, the neuropathologists were also asked to describe if there were regions showing distinct oligodendroglial morphological features. Histological evaluations were blinded to the molecular genetic data.

	Molecular Genetic Analysis.

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS Molecular Genetic Analysis. RESULTS DISCUSSION REFERENCES

 
LOH and single-strand conformational polymorphism assays were performed using the Genetic Analyzer 310 (PE Biosystems, Norwalk, CT) capillary electrophoresis system, following the manufacturer’s protocols. For the LOH assay, the following microsatellite markers located at the most frequently deleted sites in gliomas were used: D1S244, D1S2734, and D1S402 for 1p (1p36); D19S112, D19S596, D19S412, and D19S219 for 19q (19q13); and D10S1744, D10S1680, and D10S583 for 10q (10q22–23; Refs. 10 , 17 , and 21 ). Primer sequences for these markers are available from the Genome Database.⁴

The single-strand conformational polymorphism assay for exons 5–8 of TP53 was performed using the previously published primer pairs (7) . For each primer set, the sense and antisense primers were labeled with two different fluorescent dyes to allow specific detection of each strand. PCR products were separated by capillary electrophoresis and were analyzed with the GeneScan program (PE Biosystems) to detect tumor-specific migration shifts. Exons showing migration shifts were reamplified from the tumor DNA with nonlabeled primers, gel purified, and directly sequenced using the BigDye Terminator Sequencing Kit (PE Biosystems). The sequencing reaction products were separated and analyzed by the Genetic Analyzer 310 following the manufacturer’s protocol.

Previously described, established comparative multiplex PCR assays were used to detect gene amplification for EGFR and CDK4 and homozygous deletion of CDKN2A. (9 , 22)

	RESULTS

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS Molecular Genetic Analysis. RESULTS DISCUSSION REFERENCES

 
Of the 91 cases, the consensus histological diagnosis was AC (WHO grade 2) in 6, AA (grade 3) in 7, GBM (grade 4) in 45, OG (grade 2) in 21, AOG (grade 3) in 8, mixed OA (grade 2) in 3, and mixed AOA (grade 3) in 1 (Table 1) . Complete agreement of the initial diagnoses among all four neuropathologists was seen in 49 of 91 cases (54%): 4 AC (including 2 cases on which one neuropathlogist did not made a diagnosis), 0 AA, 36 GBM, 6 OG, 3 AOG, 1 OA, and 1 AOA. Disagreement was much more common in AA (seven of seven, 100%), OA (two of three, 67%), OG (15 of 21, 71%), and AOG (five of eight, 63%), compared with AC (two of eight, 25%) and GBM (9 of 45, 20%; Fig. 1, A–D ).

View larger version (84K): [in this window] [in a new window]   Fig. 1. Histological findings and molecular genetic data of representative cases. In A, case 60 was unanimously diagnosed as OG with homogeneous, round tumor cells with perinuclear halo and was 1pLOH(+), 19qLOH(+), and 10qLOH(-). In B, case 76 was OG on the consensus diagnosis but initially had diagnostic disagreement, such as AC or OA. Genetic test showed 1pLOH(-), 19qLOH(-), 10qLOH(-), and TP53 mutation (+). In C, case 83 was unanimously diagnosed as AOG and had 1pLOH(+), 19qLOH(+), and 10qLOH(-). In D, case 27 was unanimously diagnosed as GBM but had some portions with oligodendroglial features showing small, round cells with perinuclear halo. The tumor was 19qLOH(+) and 10qLOH(+) but had no 1p loss.

Among the 30 cases with 1pLOH, 25 cases (86%) also had 19qLOH: one of one AC (100%), 6 of 10 GBM (60%), 11 of 12 OG (92%), five of five AOG (100%), and two of two OA (100%). The positive correlation between 1pLOH and 19qLOH was statistically significant not only in the 34 tumors with oligodendroglial features (OG, AOG, OA, and AOA, P < 0.0001; Fisher’s exact test) but also within the 58 astrocytic tumors (AC, AA, and GBM); of 11 astrocytic tumors with 1pLOH in total, 7 (64%) had 19qLOH (P = 0.0055).

At least one of the three examined 10q markers was informative in 88 cases, and LOH was detected in 29 cases (33%): 1 AC, 1 AA, and 27 GBM. Among the 43 cases with either 1p or 19qLOH, 14 cases had 10qLOH, and 29 cases retained both copies of 10q. All of the 14 cases (100%) with 10qLOH were GBMs, whereas 25 of 29 cases (86%) retaining both copies of 10q were OG, AOG, OA, or AOA.

Mutation of TP53 was detected in 24 cases: three of six AC (50%), four of seven AA (57%), 9 of 45 GBM (20%), 6 of 21 OG (29%), zero of nine AOG (0%), one of three OA (33%), and one of one AOA (100%). When correlation with 1p status was examined, only one GBM (case 17) had both 1pLOH and TP53 mutation, and none of the remaining 29 cases with 1pLOH had TP53 mutation. This relative exclusiveness between 1pLOH and TP53 mutation was statistically significant when examined in all cases (P = 0.0003) but did not reach statistical significance when the 58 astrocytic tumors (AC, AA, and GBM) were separately analyzed, probably because a considerable number of cases had neither of the two genetic alterations (P = 0.055). On the other hand, TP53 mutation and 19qLOH were not inversely correlated in all gliomas (P = 0.29), with seven cases showing both 19qLOH and TP53 mutation: two AA, three GBM, one OG, and one AOA.

Homozygous deletion of CDKN2A was observed in one AC, one AA, 17 GBM, two OG, three AOG, and in none of OA or AOA. There was no significant association of CDKN2A status with 1pLOH, 19qLOH, or TP53 mutation in any tumor types. However, CDKN2A deletion positively correlated with 10qLOH (P = 0.04).

Gene amplification of EGFR was detected in 11 cases: 10 GBMs and 1 OG. In agreement with previous studies, most GBM cases with EGFR amplification (9 of 10) had 10qLOH, but only one had TP53 mutation (23, 24, 25) . However, this inverse correlation did not reach statistical significance in this series (P = 0.15). There was no apparent correlation between EGFR amplification and 1p/19q status: two had both 1pLOH and 19qLOH, one had 1pLOH alone, two had 19qLOH alone, and four had neither 1p nor 19qLOH. Of the 45 GBMs, 12 cases were described to contain portions with oligodendroglial morphological features. Five of the 12 cases (42%) had 19qLOH, and only 1 (8%) had 1pLOH (Table 1 ; Fig. 1D ) .

	DISCUSSION

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS Molecular Genetic Analysis. RESULTS DISCUSSION REFERENCES

 
The data presented here showed that molecular genetic evaluation of chromosomes 1p, 19q, and 10q in diffuse gliomas has significant diagnostic value, especially in identifying OGs and OAs. When 1p or 19qLOH was detected without 10qLOH in diffuse gliomas, the tumor usually demonstrated consensus oligodendroglial histological features, compatible with the diagnosis of grade II or III OG or OA. A recent study using real-time quantitative PCR to detect allelic loss also showed this concordance between 1p/19q/10q status and the histological diagnosis of OGs (26) . When 1p or 19qLOH was accompanied by additional 10qLOH, on the other hand, such tumors were most likely (86%) GBMs on consensus diagnosis. Interestingly, tumors unanimously agreed as OGs on their initial diagnoses almost always carried combined loss of 1p and 19q; all six OGs and two of three AOGs with unanimous diagnosis had 1p and 19q losses, and the remaining one AOG had 19q loss with noninformative 1p markers (Fig. 1, A and C) . Therefore, it appears that tumors showing typical histological features of OGs are likely to carry 1p and 19q losses both in grade II and grade III tumors. On the contrary, all nine consensus OGs without 1p loss had disagreement on the diagnosis initially, indicating that these might be the cases potentially leading to the diagnostic variability (Fig. 1B) .

The distinction between OG, OA, and AC can be subjective and sometimes difficult, especially in high-grade, undifferentiated tumors (20 , 27) . Our study suggested that simple LOH analysis of 1p, 19q, and 10q may provide important supportive information in making diagnoses for such difficult cases, which may affect the clinical management. For instance, a trend in postsurgical treatment for OGs is to start with chemotherapy alone and defer radiation therapy until the tumors show progression (28, 29, 30) . Whether a similar approach is appropriate in treating patients with OAs or AOAs remains to be investigated, and to do so requires homogeneous defined sets of tumors. Genetic profiles on 1p/19q/10q and TP53 should be one of the important objective factors to be considered in such studies.

There was a small number of outlying cases in our series: one AC, one AA, and one GBM showed 1p and 19qLOH while maintaining allelic balance at 10q, the typical genetic profile for OGs. Therefore, molecular genetic analysis cannot replace histological diagnosis. On the other hand, it is still unknown which of the two measures, histological diagnosis or genetic profiling, would better represent the biological characteristics of a tumor when the two evaluations disagree.

As reported previously, 1p LOH was highly associated with 19qLOH in oligodendroglial tumors, but our study further showed that this positive correlation seems to extend to astrocytic tumors, including GBMs (P = 0.0055; Refs. 13 31 , and 32 ). Although they showed such a strong positive correlation, 1pLOH and 19qLOH did have slight differences in their patterns of appearance. 1pLOH demonstrated a tight inverse correlation with TP53 mutation (P = 0.0003), a presumed key genetic event in AC tumorigenesis (2 , 33, 34, 35) . On the other hand, 19qLOH accompanied TP53 mutation more frequently both in oligodendroglial tumors and GBMs. On the basis of such findings, it is tempting to hypothesize that diffuse gliomas with 1pLOH may constitute a genetic subset that is associated with oligodendroglial lineage, whereas TP53 mutation represents another subset associated with astrocytic lineage. Such proposition has been made previously on OA, in which 1p/19qLOH was associated to be more OG predominant, and TP53 mutation was associated with more AC predominant morphology (36) . Curiously, however, partial oligodendroglial morphological features in GBMs were more frequently detected in tumors with 19q loss in our study, not in 1p loss, indicating that morphological features do not necessary follow the genetic profile (Fig. 1D) .

Genetic subsets in gliomas were first noticed in GBMs, in which TP53 mutation and EGFR gene amplification occur in a mutually exclusive fashion, thereby defining two genetic subsets (23 , 25) . Clinical significance of these genetic subsets, one with TP53 mutation and the other with EGFR amplification, was shown by the fact that secondary GBMs mostly belonged to the former, and primary GBMs mostly belonged to the latter (20 , 25) . Whether the putative subsets by 1p loss and TP53 mutation suggested in our study also would have any clinical relevance remains to be investigated. However, it is noteworthy that AOGs with 1pLOH had already been shown to have better treatment response and prognosis (16 , 17) , and another recently published study on seven high-grade gliomas with unusual long survival demonstrated 1pLOH in all seven cases (37) . Although such association was not proven in OA and astrocytic tumors thus far (17) , it is therefore possible that 1pLOH may be a marker indicative of gliomas associated with better treatment response and survival. Unfortunately, we currently do not have sufficient follow-up data on our series to look for correlation between the genetic data and clinical outcomes, such as the difference between GBMs with or without 1pLOH. Additional studies in a larger series with sufficient follow-up should address this clinically important question. Nonetheless, use of molecular genetic markers will allow objective evaluation of diffuse gliomas and, therefore, enable such studies to be done, perhaps without the time-consuming and difficult requirement of independent histological review by multiple neuropathologists.

	ACKNOWLEDGMENTS

 
We thank David N. Louis for helpful discussions concerning the manuscript. We also thank Chizu Kobayashi and Reiko Matsu-ura for their excellent technical assistance.

	FOOTNOTES

 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ Supported in part by Grant-in-Aid 13470824 from the Ministry of Education, Culture, Sports, Science and Technology, Japan, a Grant-in Aid from The Cell Science Research Foundation, and a Grant-in-Aid from The Vehicle Racing Commemorative Foundation.

² To whom requests for reprints should be addressed, at Department of Neurosurgery, The University of Tokyo Hospital, Hongo 7-3-1, Bunkyo-ku, Tokyo 113-8655, Japan. Phone: 81-3-5800-8853; Fax: 81-3-5800-8655; E-mail: kueki-tky{at}umin.ac.jp

³ The abbreviations used are: EGFR, epidermal growth factor receptor; CDK, cyclin-dependent kinase; LOH, loss of heterozygosity; AA, anaplastic astrocytoma; AC, astrocytoma; GBM, glioblastoma; OG, oligodendroglioma; AOG, anaplastic oligodendroglioma; OA, oligoastrocytoma; AOA, anaplastic oligoastrocytoma.

⁴ Internet address: http://www.gdb.org.

Received 7/16/01; revised 10/ 8/01; accepted 10/ 8/01.

	REFERENCES

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS Molecular Genetic Analysis. RESULTS DISCUSSION REFERENCES

 

1. Louis D. N., Gusella J. F. A tiger behind many doors: multiple genetic pathways to malignant glioma. Trends Genet., 11: 412-415, 1995.[CrossRef][Medline]
2. Louis D. N. A molecular genetic model of astrocytoma histopathology. Brain Pathol., 7: 755-764, 1997.[Medline]
3. Collins V. P. Progression as exemplified by human astrocytic tumors. Semin. Cancer Biol., 9: 267-276, 1999.[CrossRef][Medline]
4. Smith J. S., Jenkins R. B. Genetic alterations in adult diffuse glioma: occurrence, significance, and prognostic implications. Front. Biosci., 5: D213-D231, 2000.[Medline]
5. Bigner S. H., Burger P. C., Wong A. J., Werner M. H., Hamilton S. R., Muhlbaier L. H., Vogelstein B., Bigner D. D. Gene amplification in malignant human gliomas: clinical and histopathologic aspects. J. Neuropathol. Exp. Neurol., 47: 191-205, 1988.[Medline]
6. Reifenberger G., Reifenberger J., Ichimura K., Meltzer P. S., Collins V. P. Amplification of multiple genes from chromosomal region 12q13–14 in human malignant gliomas: preliminary mapping of the amplicons shows preferential involvement of CDK4, SAS, and MDM2. Cancer Res., 54: 4299-4303, 1994.[Abstract/Free Full Text]
7. Fults D., Brockmeyer D., Tullous M. W., Pedone C. A., Cawthon R. M. p53 mutation and loss of heterozygosity on chromosomes 17 and 10 during human astrocytoma progression. Cancer Res., 52: 674-679, 1992.[Abstract/Free Full Text]
8. Henson J. W., Schnitker B. L., Correa K. M., von Deimling A., Fassbender F., Xu H. J., Benedict W. F., Yandell D. W., Louis D. N. The retinoblastoma gene is involved in malignant progression of astrocytomas. Ann. Neurol., 36: 714-721, 1994.[CrossRef][Medline]
9. Ueki K., Ono Y., Henson J. W., Efird J. T., von Deimling A., Louis D. N. CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. Cancer Res., 56: 150-153, 1996.[Abstract/Free Full Text]
10. Steck P. A., Pershouse M. A., Jasser S. A., Yung W. K., Lin H., Ligon A. H., Langford L. A., Baumgard M. L., Hattier T., Davis T., Frye C., Hu R., Swedlund B., Teng D. H., Tavtigian S. V. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat. Genet., 15: 356-362, 1997.[CrossRef][Medline]
11. Mollenhauer J., Wiemann S., Scheurlen W., Korn B., Hayashi Y., Wilgenbus K. K., von Deimling A., Poustka A. DMBT1, a new member of the SRCR superfamily, on chromosome 10q25.3–26.1 is deleted in malignant brain tumours. Nat. Genet., 17: 32-39, 1997.[CrossRef][Medline]
12. von Deimling A., Louis D. N., von Ammon K., Petersen I., Wiestler O. D., Seizinger B. R. Evidence for a tumor suppressor gene on chromosome 19q associated with human astrocytomas, oligodendrogliomas, and mixed gliomas. Cancer Res., 52: 4277-4279, 1992.[Abstract/Free Full Text]
13. Reifenberger J., Reifenberger G., Liu L., James C. D., Wechsler W., Collins V. P. Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am. J. Pathol., 145: 1175-1190, 1994.[Abstract]
14. Smith J. S., Alderete B., Minn Y., Borell T. J., Perry A., Mohapatra G., Hosek S. M., Kimmel D., O’Fallon J., Yates A., Feuerstein B. G., Burger P. C., Scheithauer B. W., Jenkins R. B. Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype. Oncogene, 18: 4144-4152, 1999.[CrossRef][Medline]
15. Bigner S. H., Matthews M. R., Rasheed B. K., Wiltshire R. N., Friedman H. S., Friedman A. H., Stenzel T. T., Dawes D. M., McLendon R. E., Bigner D. D. Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization. Am. J. Pathol., 155: 375-386, 1999.[Abstract/Free Full Text]
16. Cairncross J. G., Ueki K., Zlatescu M. C., Lisle D. K., Finkelstein D. M., Hammond R. R., Silver J. S., Stark P. C., Macdonald D. R., Ino Y., Ramsay D. A., Louis D. N. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J. Natl. Cancer Inst. (Bethesda), 90: 1473-1479, 1998.[Abstract/Free Full Text]
17. Smith J. S., Perry A., Borell T. J., Lee H. K., O’Fallon J., Hosek S. M., Kimmel D., Yates A., Burger P. C., Scheithauer B. W., Jenkins R. B. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J. Clin. Oncol., 18: 636-645, 2000.[Abstract/Free Full Text]
18. Bigner S. H., Mark J., Burger P. C., Mahaley M. S., Bullard D. E., Muhlbaier L. H., Bigner D. D. Specific chromosomal abnormalities in malignant human gliomas. Cancer Res., 48: 405-411, 1988.[Abstract/Free Full Text]
19. Ueki K., Rubio M. P., Ramesh V., Correa K. M., Rutter J. L., von Deimling A., Buckler A. J., Gusella J. F., Louis D. N. MTS1/CDKN2 gene mutations are rare in primary human astrocytomas with allelic loss of chromosome 9p. Hum. Mol. Genet., 3: 1841-1845, 1994.[Abstract/Free Full Text]
20. Kleihues, P., and Cavenee, W. K. WHO classification, Tumors of the Central Nervous System. Lyon, France: IARC, 2000.
21. Rosenberg J. E., Lisle D. K., Burwick J. A., Ueki K., von Deimling A., Mohrenweiser H. W., Louis D. N. Refined deletion mapping of the chromosome 19q glioma tumor suppressor gene to the D19S412-STD interval. Oncogene, 13: 2483-2485, 1996.[Medline]
22. Louis D. N., Rubio M. P., Correa K. M., Gusella J. F., von Deimling A. Molecular genetics of pediatric brain stem gliomas. Application of PCR techniques to small and archival brain tumor specimens. J. Neuropathol. Exp. Neurol., 52: 507-515, 1993.[Medline]
23. von Deimling A., von Ammon K., Schoenfeld D., Wiestler O. D., Seizinger B. R., Louis D. N. Subsets of glioblastoma multiforme defined by molecular genetic analysis. Brain Pathol., 3: 19-26, 1993.[Medline]
24. von Deimling A., Louis D. N., von Ammon K., Petersen I., Hoell T., Chung R. Y., Martuza R. L., Schoenfeld D. A., Yasargil M. G., Wiestler O. D., et al Association of epidermal growth factor receptor gene amplification with loss of chromosome 10 in human glioblastoma multiforme. J. Neurosurg., 77: 295-301, 1992.[Medline]
25. Watanabe K., Tachibana O., Sata K., Yonekawa Y., Kleihues P., Ohgaki H. Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol., 6: 217-223, discussion 23–24 1996.[Medline]
26. Nigro J. M., Takahashi M. A., Ginzinger D. G., Law M., Passe S., Jenkins R. B., Aldape K. Detection of 1p and 19q loss in oligodendroglioma by quantitative microsatellite analysis, a real-time quantitative polymerase chain reaction assay. Am. J. Pathol., 158: 1253-1262, 2001.[Abstract/Free Full Text]
27. Coons S. W., Johnson P. C., Scheithauer B. W., Yates A. J., Pearl D. K. Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. Cancer (Phila.), 79: 1381-1393, 1997.[CrossRef][Medline]
28. Streffer J., Schabet M., Bamberg M., Grote E. H., Meyermann R., Voigt K., Dichgans J., Weller M. A role for preirradiation PCV chemotherapy for oligodendroglial brain tumors. J. Neurol., 247: 297-302, 2000.[CrossRef][Medline]
29. Fortin D., Cairncross G. J., Hammond R. R. Oligodendroglioma: an appraisal of recent data pertaining to diagnosis and treatment. Neurosurgery, 45: 1279-1291, discussion 191 1999.[Medline]
30. Burton E., Prados M. New chemotherapy options for the treatment of malignant gliomas. Curr. Opin. Oncol., 11: 157-161, 1999.[CrossRef][Medline]
31. Kraus J. A., Koopmann J., Kaskel P., Maintz D., Brandner S., Schramm J., Louis D. N., Wiestler O. D., von Deimling A. Shared allelic losses on chromosomes 1p and 19q suggest a common origin of oligodendroglioma and oligoastrocytoma. J. Neuropathol. Exp. Neurol., 54: 91-95, 1995.[Medline]
32. Bello M. J., Leone P. E., Vaquero J., de Campos J. M., Kusak M. E., Sarasa J. L., Pestana A., Rey J. A. Allelic loss at 1p and 19q frequently occurs in association and may represent early oncogenic events in oligodendroglial tumors. Int. J. Cancer, 64: 207-210, 1995.[Medline]
33. Sidransky D., Mikkelsen T., Schwechheimer K., Rosenblum M. L., Cavanee W., Vogelstein B. Clonal expansion of p53 mutant cells is associated with brain tumour progression. Nature (Lond.), 355: 846-847, 1992.[CrossRef][Medline]
34. Bogler O., Huang H. J., Cavenee W. K. Loss of wild-type p53 bestows a growth advantage on primary cortical astrocytes and facilitates their in vitro transformation. Cancer Res., 55: 2746-2751, 1995.[Abstract/Free Full Text]
35. Ohgaki H., Schauble B., zur Hausen A., von Ammon K., Kleihues P. Genetic alterations associated with the evolution and progression of astrocytic brain tumours. Virchows Arch., 427: 113-118, 1995.[Medline]
36. Maintz D., Fiedler K., Koopmann J., Rollbrocker B., Nechev S., Lenartz D., Stangl A. P., Louis D. N., Schramm J., Wiestler O. D., von Deimling A. Molecular genetic evidence for subtypes of oligoastrocytomas. J. Neuropathol. Exp. Neurol., 56: 1098-1104, 1997.[Medline]
37. Ino Y., Zlatescu M. C., Sasaki H., Macdonald D. R., Stemmer-Rachamimov A. O., Jhung S., Ramsay D. A., von Deimling A., Louis D. N., Cairncross J. G. Long survival and therapeutic responses in patients with histologically disparate high-grade gliomas demonstrating chromosome 1p loss. J. Neurosurg., 92: 983-990, 2000.[Medline]

This article has been cited by other articles:

				A. Korshunov, R. Sycheva, and A. Golanov Molecular Stratification of Diagnostically Challenging High-Grade Gliomas Composed of Small Cells: The Utility of Fluorescence In situ Hybridization Clin. Cancer Res., December 1, 2004; 10(23): 7820 - 7826. [Abstract] [Full Text] [PDF]

				M. Wang, K. M. Murphy, P. Kulesza, K. J. Hatanpaa, A. Olivi, A. Tufaro, Y. Erozan, W. H. Westra, P. C. Burger, and K. D. Berg Molecular Diagnosis of Metastasizing Oligodendroglioma: A Case Report J. Mol. Diagn., February 1, 2004; 6(1): 52 - 57. [Abstract] [Full Text]

				F. Lerebours, P. Bertheau, I. Bieche, L.-F. Plassa, M.-H. Champeme, K. Hacene, C. Toulas, M. Espie, M. Marty, and R. Lidereau Two Prognostic Groups of Inflammatory Breast Cancer Have Distinct Genotypes Clin. Cancer Res., September 15, 2003; 9(11): 4184 - 4189. [Abstract] [Full Text] [PDF]

				R. J. Gilbertson, D. A. Hill, R. Hernan, M. Kocak, R. Geyer, J. Olson, A. Gajjar, L. Rush, R. L. Hamilton, S. D. Finkelstein, et al. ERBB1 Is Amplified and Overexpressed in High-grade Diffusely Infiltrative Pediatric Brain Stem Glioma Clin. Cancer Res., September 1, 2003; 9(10): 3620 - 3624. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ueki, K. Articles by Kirino, T. Search for Related Content PubMed PubMed Citation Articles by Ueki, K. Articles by Kirino, T.